Skip to main content

Advertisement

SpringerLink
Log in

Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). The patients were administered six cycles of induction chemotherapy consisting of intravenously (i.v.) Cis 70 mg/m2 on day 1 plus i.v. Gem 1000 mg/m2 on days 1 and 8, plus i.v. Bev 7.5 mg/kg on day 1, every 3 weeks. Patients who did not experience tumor progression remained on maintenance treatment with Bev combined with oral Vnb 60 mg/m2 weekly until occurrence of disease progression or unacceptable toxicity. Thirty-seven patients were enrolled: The median age was 67 years (range 38–81); 22 patients were male, and 30 patients had stage IV tumors. The response rate was 32.4 % (95 % CI 18–49.7). The 9-month disease-control rate was 45.9 %. The median PFS was 8.4 months (95 % CI 4.4–10.7), and the median OS was 18.1 months (95 % CI 15.3–20.8 months). Grade 3–4 neutropenia occurred in 6 (16.2 %) patients and grade 3–4 thrombocytopenia in four (10.8 %) patients during induction chemotherapy. Bev- or Vnb-associated toxicities were mild. Switch maintenance treatment with Bev and oral Vnb after first-line Cis, Gem and Bev is feasible in patients with non-squamous NSCLC and may achieve encouraging results in terms of PFS and OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  2. Schrump DS, Nguyen DM. Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol. 2005;32(5):488–502.

    Article  CAS  PubMed  Google Scholar 

  3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.

    Article  CAS  PubMed  Google Scholar 

  4. Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11:733–40.

    Article  PubMed  Google Scholar 

  5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.

    Article  CAS  PubMed  Google Scholar 

  6. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C, BO17704 Study Group. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–34.

    Article  CAS  PubMed  Google Scholar 

  7. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611.

    Article  CAS  PubMed  Google Scholar 

  9. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–49.

    Article  CAS  PubMed  Google Scholar 

  10. Zhan P, Wang J, Lv XJ, Ang Q, Qiu LX, Lin XQ, Yu LK, Song Y. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with metaanalysis. J Thorac Oncol. 2009;4:1094–103.

    Article  PubMed  Google Scholar 

  11. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-lung cancer. N Engl J Med. 2005;352:2589–97.

    Article  CAS  PubMed  Google Scholar 

  12. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–34.

    Article  CAS  PubMed  Google Scholar 

  13. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol. 2003;21:3909–17.

    Article  CAS  PubMed  Google Scholar 

  14. Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O’Brien M, Puozzo C. Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs. 2007;67(10):1403–10.

    Article  CAS  PubMed  Google Scholar 

  15. Gridelli C, Manegold C, Mali P, Reck M, Portalone L, Castelnau O, Stahel R, Betticher D, Pless M, Pons JT, Aubert D, Burillon JP, Parlier Y, De Marinis F. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer. 2004;40(16):2424–31.

    Article  CAS  PubMed  Google Scholar 

  16. Kanard A, Jatoi A, Castillo R, Geyer S, Schulz TK, Fitch TR, Rowland KM, Nair S, Krook JE, Kugler JW. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer. 2004;3(3):345–53.

    Article  Google Scholar 

  17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  18. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Tur NF, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004–11.

    Article  CAS  PubMed  Google Scholar 

  19. Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015;10(1):134–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Dranitsaris G, Beegle N, Ravelo A, Kalberer T, Yu E, Thomas S. Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced non-small-cell lung cancer. Clin Lung Cancer. 2013;14(2):120–7.

    Article  CAS  PubMed  Google Scholar 

  21. Owonikoko TK, Ramalingam SS, Belani CP. Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res. 2010;16:2496–504.

    Article  CAS  PubMed  Google Scholar 

  22. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5:203–20.

    Article  CAS  PubMed  Google Scholar 

  23. Mancuso MR, Davis R, Norberg SM, O’Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C. Gridelli C maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–55.

    Article  CAS  PubMed  Google Scholar 

  25. Perol M, Chouaid C, Perol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin–gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516–24.

    Article  CAS  PubMed  Google Scholar 

  26. Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer. 2005;48(1):129–35.

    Article  PubMed  Google Scholar 

  27. Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer. 2009;64(3):319–25.

    Article  PubMed  Google Scholar 

  28. Lilenbaum R, Villaflor VM, Langer C, O’Byrne K, O’Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009;4:869–74.

    Article  PubMed  Google Scholar 

  29. Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati S, Rondini M, Tartarelli G, Puccinelli P, Di Costanzo F, Amoroso D. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol. 2010;21(6):1290–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

The study has been approved by the local institutional research ethical committee, and all procedures performed in human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations

  1. Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Bracci, 53100, Siena, Italy

    Roberto Petrioli, Letizia Laera & Giandomenico Roviello

  2. Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, Italy

    Edoardo Francini & Vincenzo Bianco

  3. Pharmacology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy

    Anna Ida Fiaschi

  4. Unit of Thoracic Surgery, Surgery Department, University of Siena, Siena, Italy

    Luca Luzzi, Piero Paladini & Claudia Ghiribelli

  5. Unit of Thoracic Surgery, Policlinico Careggi, University of Firenze, Florence, Italy

    Luca Voltolini

Authors
  1. Roberto Petrioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edoardo Francini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Ida Fiaschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Letizia Laera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luca Luzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Piero Paladini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Claudia Ghiribelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luca Voltolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vincenzo Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giandomenico Roviello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Petrioli.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrioli, R., Francini, E., Fiaschi, A.I. et al. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol 32, 134 (2015). https://doi.org/10.1007/s12032-015-0587-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0587-x

Keywords

Search

Navigation